Pfizer is a research-based biopharmaceutical company, developing and manufacturing human and veterinary medicines, as well as consumer healthcare products. The Company applies science and its global resources to improve health and well-being at every stage of life. Its diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products, and many consumer health care products. The Company operates in two business segments: biopharmaceutical and diversified. Biopharmaceutical segment includes the primary and specialty care, established products, emerging markets and oncology customer-focused units. Diversified segment offers animal health products that prevent and treat diseases in livestock and companion animals, and consumer healthcare products. Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain. 

Show more
Type
Public
HQ
New York, US
Founded
1849
Size (employees)
90,200 (est)-6%
Website
pfizer.com
Pfizer was founded in 1849 and is headquartered in New York, US
Report incorrect company information

Key People/Management at Pfizer

Ian Read

Ian Read

Chairman of the Board and Chief Executive Officer
Doug Lankler

Doug Lankler

Executive Vice President, General Counsel
Chuck Hill

Chuck Hill

Executive Vice President, Worldwide Human Resources
Mikael Dolsten

Mikael Dolsten

President, Worldwide Research and Development and Executive Vice President of Pfizer Inc
Albert Bourla

Albert Bourla

Chief Operating Officer, Pfizer
Frank D'Amelio

Frank D'Amelio

Executive Vice President, Business Operations and Chief Financial Officer
Show more

Pfizer Office Locations

Pfizer has offices in Surrey, Zürich, Sollentuna, Alcobendas and in 36 other locations
New York, US (HQ)
235 E 42nd St
Buenos Aires, AR
Panamericana Collector 1804, 1st Floor - Sector B - South Side
Melrose Park, AU
38-42 Wharf Rd
Wien, AT
1 Floridsdorfer Hauptstraße
Minsk, BY
403 8 praspiekt Dziaržynskaha
Ixelles, BE
17 Boulevard de la Plaine
Show all (40)
Report incorrect company information

Pfizer Financials and Metrics

Pfizer Financials

Pfizer's revenue was reported to be $52.82 b in FY, 2016 which is a 8.1% increase from the previous period.
USD

Revenue (Q2, 2017)

12.9 b

Market capitalization (23-Apr-2018)

222.9 b
Pfizer's current market capitalization is $222.9 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

51.6 b49.6 b48.9 b52.8 b

Revenue growth, %

(4%)(2%)8%

Cost of goods sold

9.6 b9.6 b9.6 b12.3 b

Gross profit

42 b40 b39.2 b40.5 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q2, 2017

Revenue

12.6 b11.4 b12.8 b12.4 b10.9 b11.9 b12.1 b12.9 b

Cost of goods sold

2.3 b2 b2.5 b2.4 b1.8 b

Gross profit

10.4 b9.3 b10.3 b10 b9 b

Gross profit Margin, %

82%82%81%81%83%
Annual
usdY, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.2 b10.1 b2.2 b3.3 b3.6 b

Inventories

6.2 b5.7 b

Current Assets

56.2 b57.7 b43.8 b38.9 b

PP&E

12.4 b11.8 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q3, 2016Q1, 2016Q2, 2016Q1, 2017Q2, 2017

Cash

2.1 b2.9 b3.4 b2.4 b3.6 b3.7 b3.1 b

Inventories

6.5 b6.1 b6.2 b6.4 b5.8 b5.8 b7.6 b7.6 b

Current Assets

59.5 b57.8 b58.3 b57 b49.4 b51.7 b45 b38.5 b41.3 b43.8 b35.9 b36.4 b

PP&E

12.4 b12.3 b12.2 b12 b11.5 b11.4 b13.7 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

22.1 b9.2 b

Inventories

(538 m)175 m(199 m)365 m

Accounts Payable

382 m297 m254 m871 m

Cash From Operating Activities

17.8 b16.9 b14.5 b15.9 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2017

Net Income

2.6 b2.3 b2.9 b2.7 b2.4 b

Depreciation and Amortization

3.1 b

Cash From Operating Activities

4.8 b

Purchases of PP&E

(806 m)
USDY, 2017

Revenue/Employee

133.6 k

Financial Leverage

2.9 x
Show all financial metrics

Pfizer Operating Metrics

Y, 2014Y, 2015Y, 2016

Active Clinical Studies

448 338

Discovery Projects

91 90 96

Drugs Approved by FDA

1

Phase III Trials Products

22 30 34
Show all operating metrics

Pfizer Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Medivation August 22, 2016$14 b
Anacor Pharmaceuticals June 24, 2016$5.20 b
Allergan November 23, 2015$160 b
Report incorrect company information

Pfizer News and Updates

United States Sexually Transmitted Diseases Drug Market: Industry Trends, Share, Size and 2025 Future Report

Sexually Transmitted Diseases Drug Market: Rising Incidence of Sexually Transmitted Diseases Fuels Demand for Effective Drugs.Sexually Transmitted Diseases Drug Market to Reach US$ 83.04 Billion by 2025: Posted via Industry Today. Follow us on Twitter @IndustryToday

FDA to Pfizer: To win OK for Herceptin biosimilar, fork over more 'technical' info

U.S. regulators knocked back Pfizer's biosimilar version of Roche's breast cancer stalwart Herceptin, the drug giant's second biosim knockoff to fall short at the FDA. The delay will put Pfizer even farther behind Mylan and Biocon, which nabbed an FDA green light in December.

Pfizer's first U.K. ads for OTC Viagra put erectile dysfunction in perspective

Pfizer’s first ad campaign for over-the-counter Viagra in the U.K. uses comparisons to illustrate the relative commonplace incidence of erectile dysfunction. Print and out-of-home ads begin with the fact that “4.3 million men in the U.K. experience erectile problems.” The text-heavy ads then note co…

Zolmitriptan Nasal Spray Market Analysis, Market Size, Regional Outlook, Competitive Strategies and Forecasts, 2017 To 2022, Focusing On Top Key Vendors: Pfizer, Bayer, AptarGroup, Merck, Sanofi

The Global Zolmitriptan Nasal Spray Market Report includes a comprehensive analysis of the present market. The report starts with the basic Zolmitriptan Nasal Spray Market overview and then goes into each and every detail. Posted via Industry Today. Follow us on Twitter @IndustryToday

Clinical Trial Management System Market Key Developments 2018 | Company Overview with Forte Research Systems, eClinForce, iWEb Technologies and more.

Latest research study from Market Research Future with title Global Clinical trial management system Market by Manufacturers, Regions, Type and Application, Forecast to 2023. The Research report presents a complete assessment of the market and contains Future trend and Current Growth Factors. Posted…

Generic Injectable Market Analysis and Forecast by Future Market Insights

Generic Injectable Market Analysis and Forecast by Future Market Insights Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more
Report incorrect company information